Anine Larsen Ottestad

Mrs. Anine Larsen Ottestad

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
AOAnine Larsen Ottestad
Anine Larsen Ottestad
MHMo Huang
Mo Huang
EEElisabeth Emdal
Elisabeth Emdal
RMRobin Mjelle
Robin Mjelle
VSVeronica Skarpeteig
Veronica Skarpeteig
HDHong Yan Dai
Hong Yan Dai
(1) Background: Analysis of tumor DNA by next-generation sequencing (NGS) plays various roles in the classification and management of cancer. This study aimed to assess the performance of two similar and large, comprehensive gene panels with a focus on clinically relevant variant detection and tumor mutation burden (TMB) assessment; (2) Methods: DNA from 19 diagnostic small cell lung cancer biopsies and an AcroMetrix™ assessment sample with >500 mutations were sequenced using Oncomine™ Comprehensive Assay Plus (OCAP) on the Ion Torrent platform and TruSight Oncology 500 Assay (TSO500) on the Illumina platform; (3) Results: OCAP and TSO500 achieved comparable NGS quality, such as mean read coverage and mean coverage uniformity. A total of 100% of the variants in the diagnostic samples and 80% of the variants in the AcroMetrix™ assessment sample were detected by both panels, and the panels reported highly similar variant allele frequency. A proportion of 14/19 (74%) samples were classified in the same TMB category; (4) Conclusions: Comparable results were obtained using OCAP and TSO500, suggesting that both panels could be applied to screen patients for enrolment in personalized cancer treatment trials.

11 July 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AOAnine Larsen Ottestad
Anine Larsen Ottestad
HJHåkon Johansen
Håkon Johansen
THTarje Onsøien Halvorsen
Tarje Onsøien Halvorsen
HDHong Yan Dai
Hong Yan Dai
SWSissel Gyrid Freim Wahl
Sissel Gyrid Freim Wahl
BGBjørn Henning Grønberg
Bjørn Henning Grønberg
Background: The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic NSCLC indicate that ctDNA levels are associated with tumor metabolic activity as measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). This study investigated this association in NSCLC patients considered for potentially curative treatment and explored whether the two methods provide independent prognostic information. Method: Patients with stage I-III NSCLC who had routinely undergone an 18F-FDG PET/CT scan and exploratory ctDNA analyses were included. Tumor glucose uptake was measured by maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from the 18F-FDG PET/CT scans. ctDNA detectability and quantity, using variant allele frequency, were estimated by tumor-informed ctDNA analyses. Results: In total, 63 patients (median age 70 years, 60% women, and 90% adenocarcinoma) were included. The tumor glucose uptake (SUVmax, MTV, and TLG) was significantly higher in patients with detectable ctDNA (n = 19, p < 0.001). The ctDNA quantity correlated with MTV (Spearman’s ρ = 0.53, p = 0.021) and TLG (Spearman’s ρ = 0.56, p = 0.013) but not with SUVmax (Spearman’s ρ = 0.034, p = 0.15). ctDNA detection was associated with shorter OS independent of MTV (HR: 2.70, 95% CI: 1.07–6.82, p = 0.035) and TLG (HR: 2.63, 95% CI: 1.06–6.51, p = 0.036). Patients with high tumor glucose uptake and detectable ctDNA had shorter overall survival and progression-free survival than those without detectable ctDNA, though these associations were not statistically significant (p > 0.05). Conclusion: There was a positive correlation between plasma ctDNA quantity and MTV and TLG in early-stage NSCLC patients. Despite the correlation, the results indicated that ctDNA detection was a negative prognostic factor independent of MTV and TLG.

1 February 2020 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
AOAnine Larsen Ottestad
Anine Larsen Ottestad
SWSissel G.F. Wahl
Sissel G.F. Wahl
BGBjørn Grønberg
Bjørn Grønberg
FSFrank Skorpen
Frank Skorpen
HDHong Yan Dai
Hong Yan Dai

20 July 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AOAnine Larsen Ottestad
Anine Larsen Ottestad
HJHåkon Johansen
Håkon Johansen
THTarje Onsøien Halvorsen
Tarje Onsøien Halvorsen
HDHong Yan Dai
Hong Yan Dai
SWSissel Gyrid Freim Wahl
Sissel Gyrid Freim Wahl
BGBjørn Henning Grønberg
Bjørn Henning Grønberg

1 October 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SWS.G.F. Wahl
S.G.F. Wahl
HDH.Y. Dai
H.Y. Dai
EEE.F. Emdal
E.F. Emdal
AOAnine Larsen Ottestad
Anine Larsen Ottestad
ERE. Richardsen
E. Richardsen
BGB.H. Gronberg
B.H. Gronberg